These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16628715)

  • 1. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
    Ural AU; Avcu F
    Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715
    [No Abstract]   [Full Text] [Related]  

  • 2. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
    Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
    Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide with continuous low-dose dexamethasone for multiple myeloma.
    Gardyn J
    J Clin Oncol; 2005 Feb; 23(6):1323. PubMed ID: 15718336
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
    Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
    Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
    Richardson P; Anderson K
    J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
    [No Abstract]   [Full Text] [Related]  

  • 7. Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma.
    Greipp PR
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):188-9. PubMed ID: 16224404
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 11. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
    Bemardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):129-33. PubMed ID: 16767919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of elderly patients with multiple myeloma.
    Facon T
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):501-2. PubMed ID: 17147234
    [No Abstract]   [Full Text] [Related]  

  • 15. Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation.
    Blade J
    Haematologica; 2005 Dec; 90(12):1589. PubMed ID: 16330426
    [No Abstract]   [Full Text] [Related]  

  • 16. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combo drug therapy beneficial for new cases of multiple myeloma.
    Health News; 2006 Feb; 12(2):9. PubMed ID: 16456922
    [No Abstract]   [Full Text] [Related]  

  • 18. Comment on thalidomide usage in myeloma.
    Myers B
    Haematologica; 2002 Jun; 87(6):ELT29. PubMed ID: 12031937
    [No Abstract]   [Full Text] [Related]  

  • 19. Ultra low dose thalidomide in myeloma revisited.
    Patrick HE; Bowcock SJ
    Br J Haematol; 2010 Jul; 150(2):232-4. PubMed ID: 20346009
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.